Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Ipsen, a global biopharmaceutical group, and Invida Group, the leading healthcare commercialization solutions partner in the Asia Pacific region, announced today an agreement for the exclusive distribution and promotion by Invida of Ipsen's drugs Diphereline® 3.75mg & 11.25mg, Somatuline® Autogel® and Increlex® in selected countries in South-East Asia.

27 Apr 2010

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has renewed a supply agreement for its full product line of automated and semi-automated urinalysis systems, related products, consumables and services agreements, with MedAssets Supply Chain Systems, one of the largest Group Purchasing Organizations (GPOs) serving healthcare providers nationwide. The new three-year contract is effective April 1, 2010.

26 Apr 2010

Programs to address care for children born with SCD during adulthood

Forty years ago, children born with sickle cell disease (SCD) were not expected to live past their teenage years. Today, medical advances are allowing children to live well into adulthood, raising concerns over who is going to care for these patients as adults. However, programs are underway to address these concerns, as reported in the March/April edition of Journal of Pediatric Oncology Nursing, published by the Association of Pediatric Hematology/Oncology Nurses (APHON).

24 Apr 2010

CAT may improve QOL in pediatric oncology patients undergoing therapy: Researchers

As health care professionals continue placing greater emphasis on the quality of life of childhood cancer patients, researchers have found that creative arts therapy may improve QOL in pediatric oncology patients undergoing therapy.

24 Apr 2010

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

IDEXX Laboratories, Inc., today reported that revenues for the first quarter of 2010 increased 14% to $268.5 million, from $236.5 million for the first quarter of 2009. Organic revenue growth, as defined below, was 9%. Earnings per diluted share for the quarter ended March 31, 2010 increased 28% to $0.55, compared to $0.43 for the same period in the prior year.

23 Apr 2010

EpiCept invites stockholders to attend Annual Meeting

With this notice, stockholders of EpiCept Corporation are invited to the Annual Meeting of Stockholders on June 3, 2010, at 10:00 a.m. Eastern time at the Dolce/IBM Palisades Executive Conference Center, 334 Route 9W, Palisades, New York 10964.

23 Apr 2010

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

BSD Medical Corporation today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.

23 Apr 2010

HemaQuest Pharmaceuticals closes $12M Series B financing

HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing compounds to treat sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures. HemaQuest's investor syndicate includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

21 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Hematological malignancies conference to provide update on blood-borne cancer

John Theurer Cancer Center at Hackensack University Medical Center will host a hematological malignancies conference for physicians and patients on Friday, April 23 and Saturday, April 24. The event, entitled "Current and Innovative Modalities in the Management of Hematological Malignancies", is part of John Theurer Cancer Center's commitment to provide both healthcare professionals as well as patients with an update on the newest advances in the field of blood-borne cancers.

20 Apr 2010

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced an extension to its award-winning CompoZr® product offering with the global release of the CompoZr Targeted Integration Kit, AAVS1. This kit provides a powerful method for the controlled transgene integration and expression of any gene in any human cell line using Sigma-Aldrich's proprietary CompoZr Zinc Finger Nuclease (ZFN) technology.

20 Apr 2010

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.

20 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.

19 Apr 2010

NDA for Cadence Pharmaceuticals' OFIRMEV injection to be re-submitted to FDA

Cadence Pharmaceuticals, Inc. announced today that, based on feedback received during a meeting with the U.S. Food and Drug Administration on April 16, 2010, it plans to re-submit a New Drug Application for its investigational product candidate, OFIRMEV (acetaminophen) injection, within the next 30 days.

19 Apr 2010

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

19 Apr 2010

New drug to stop the growth of prostate cancer tumors investigated

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

17 Apr 2010

Nine-year-old cancer patient benefits from procedure to magnetically extend her leg

Nine-year-old Morgan LaRue is the first cancer patient in Texas to benefit from a groundbreaking procedure that will magnetically lengthen her leg, sparing her the possibility of up to 10 future surgeries as her body grows. The implant and extension took place at Texas Children's Cancer Center in Houston, Texas.

16 Apr 2010

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).

16 Apr 2010

Hematology News and Research

Further Reading

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

Programs to address care for children born with SCD during adulthood

CAT may improve QOL in pediatric oncology patients undergoing therapy: Researchers

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

EpiCept invites stockholders to attend Annual Meeting

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

HemaQuest Pharmaceuticals closes $12M Series B financing

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Hematological malignancies conference to provide update on blood-borne cancer

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

NDA for Cadence Pharmaceuticals' OFIRMEV injection to be re-submitted to FDA

New p53 knockout rat model improves timelines for carcinogenicity screening

New drug to stop the growth of prostate cancer tumors investigated

Nine-year-old cancer patient benefits from procedure to magnetically extend her leg

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo